Source:http://linkedlifedata.com/resource/pubmed/id/10705305
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2000-4-5
|
| pubmed:abstractText |
Immunological control of acute leukemia may be achieved after allogeneic transplant. Despite promising preliminary results, the impact of immunotherapy with interleukin-2 (r-IL-2) on patients with acute leukemia (AL), in first complete remission (CR1) remains unclear. We conducted a prospective multicenter randomized trial to compare outcome in patients with AL in CR1, treated with autologous bone marrow transplantation (BMT) with or without postgraft r-IL-2. One hundred and thirty patients with AL in CR1 (myeloblastic (AML): N = 78; lymphoblastic (ALL): N = 52) were randomized at time of BMT to receive (N = 65) or not (N = 65) r-IL-2. r-IL-2 (RU 49637 from Roussel Uclaf) was started after hematological recovery, as a five cycle regimen (12 M IU/m2/day continuous infusion on day 1-5, 15-17, 29-31,43-45 and 57-59). The two groups were balanced for patient and transplant characteristics. Analysis was based on an intent to treat. Thirty-eight (59%) of the 65 patients randomized into the study group started r-IL-2 at a median of sixty-eight days (23-140) after transplant and received 77% (16-100) of the scheduled dosage. They received a median of 120 x 10(6) IU/m2 (25-156) over 10 (3-13) days during a total median period of 56 (3-78) days. With a median follow-up of 7 years (5.4-8.1 years), 79 patients relapsed (study group: 43 (66%); control group: 36 (55%): p = NS). Survival and leukemia-free survival estimates were 33% (23-45) versus 43% (22-52) and 29% (19-41) versus 36% (24-51) respectively for study and control groups (all p = NS). These results show that leukemic control after autologous BMT is not increased by r-IL-2 therapy. Further studies should investigate more appropriate r-IL-2 schedules and the possibilities offered by better antigen recognition and activated effector cells.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1148-5493
|
| pubmed:author |
pubmed-author:AttarSS,
pubmed-author:BellangerCC,
pubmed-author:BlaiseDD,
pubmed-author:BouabdallahRR,
pubmed-author:BrandelyMM,
pubmed-author:HercendTT,
pubmed-author:MaraninchiDD,
pubmed-author:MarisFF,
pubmed-author:MichalletMM,
pubmed-author:NagoHH,
pubmed-author:PayerGG,
pubmed-author:ReiffersJJ,
pubmed-author:RossiJ FJF,
pubmed-author:SottoJ JJJ,
pubmed-author:StoppaA MAM
|
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
91-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10705305-Adult,
pubmed-meshheading:10705305-Bone Marrow Transplantation,
pubmed-meshheading:10705305-Combined Modality Therapy,
pubmed-meshheading:10705305-Disease-Free Survival,
pubmed-meshheading:10705305-Female,
pubmed-meshheading:10705305-Follow-Up Studies,
pubmed-meshheading:10705305-Humans,
pubmed-meshheading:10705305-Interleukin-2,
pubmed-meshheading:10705305-Leukemia, Myeloid, Acute,
pubmed-meshheading:10705305-Male,
pubmed-meshheading:10705305-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:10705305-Prospective Studies,
pubmed-meshheading:10705305-Recombinant Proteins,
pubmed-meshheading:10705305-Remission Induction,
pubmed-meshheading:10705305-Survival Rate,
pubmed-meshheading:10705305-Time Factors,
pubmed-meshheading:10705305-Transplantation, Autologous,
pubmed-meshheading:10705305-Treatment Outcome
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
|
| pubmed:affiliation |
Unité de Transplantation et de Thérapie Cellulaire, Université de la Méditerranée, Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273 Marseille Cedex 9 France. blaised@marseille.fnclcc.fr
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|